Prostate Cancer Program

NIH RePORTER · NIH · P30 · $183,249 · view on reporter.nih.gov ↗

Abstract

Prostate Cancer Program: Summary/Abstract The overarching scientific goal of the HDFCCC Prostate Cancer (PR) Program is to use a team approach to advance the understanding of tumor biology and drive translation into more effective and targeted treatment. This is done through translational research spanning discovery bench science to clinical application and back. The PR Program also seeks to specifically address the burden of prostate cancer and disparities in outcomes among patients within the catchment area. The result will be a reduction the morbidity and mortality associated with prostate cancer and its treatments by leveraging a deep understanding of the disease at the biologic, clinical, and population levels. The PR Program approaches this mission with transdisciplinary research that is richly collaborative and translational, organized around three specific aims: (1) to discover molecular features and drivers of prostate cancer; (2) to develop and validate biomarkers and models to predict outcomes in men with prostate cancer; and (3) to develop clinical interventions to improve outcomes for men with prostate cancer.

Key facts

NIH application ID
10712677
Project number
2P30CA082103-24
Recipient
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Principal Investigator
ERIC J SMALL
Activity code
P30
Funding institute
NIH
Fiscal year
2023
Award amount
$183,249
Award type
2
Project period
1999-08-05 → 2028-05-31